
Developing breakthrough AXL therapeutics to improve patients’ lives
COMPANY PRESENTATIONS
Nordic Healthcare Conference 2022, 15 December 2022
15 December 2022
SCIENTIFIC PUBLICATIONS
Cell Report Medicine, Huiyu Li et al.
15th March 2022
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections
BerGenBio’s lead candidate, bemcentinib, is in Phase II clinical testing in patients with NSCLC, AML and COVID-19. As of the end of 2021, bemcentinib had been studied in over 600 patients, demonstrating its safety as a monotherapy and in combination with chemotherapy and immune checkpoint inhibition. This large safety database positions us well to advance the development of bemcentinib towards the market. Clinical data generated with bemcentinib in multiple Phase I and Phase II trials to date, confirm its potential utility as a therapy in cancer and for the treatment of COVID-19. Based on preclinical and early clinical data, we also believe bemcentinib may have the ability to enhance outcomes when combined with immunotherapy in NSCLC. Taken together, our initial data form the basis of BerGenBio’s preparations for the late-stage clinical strategy for bemcentinib.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (OSE:BGBIO).
Explore BerGenBio’s pipelineLatest News
BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations
– Global trial designed to study the safety, tolerability and efficacy of bemcentinib in combination with current standard of care – BERGEN, Norway, March 9, 2023 – BerGenBio ASA
Read moreBerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update
BERGEN, Norway, February 16, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results
Read moreBerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients
– The Company will discuss the topline results during its Q4 2022 results presentation on Thursday, February 16, 2023, at 10:00 AM CET – BERGEN, Norway, February 15, 2023
Read moreBerGenBio Announces the Establishment of Oncology Scientific Advisory Board
– Distinguished global experts appointed to strengthen bemcentinib development in STK11m NSCLC – BERGEN, Norway, February 2, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,
Read more